AKIGAI’s mission
is clear and stedfast.
“To make an EGFR-inhibitor available to as many neuropathic pain patients as possible, as quickly as possible.”
To this end, we have mapped all marketed EGFR-inhibitors and >60 development candidates that have been tested in clinical trials.
After in-silico research, experiments in rodent models, as well as years of observations in 100+ successfully treated neuropathic pain patients with 11 different pain entities, one of the EGFR-inhibitors approved for the treatment of cancer stands out.
The EGFR is one of the most studied molecules in the human body.
The Two Routes of Administration
AKIGAI's approach is twofold. We envision two paths to development of a new type of EGFR-inhibitor.
Latest news from AKIGAI
AKIGAI Welcomes Strategic Investment Partner!
AKIGAI has secured a strategic partnership with investor Brynjar Forbergskog
FDA grants Orphan Designation for the treatment of CRPS with AKI-007
Dramatic, durable and safe pain relief in chronic CRPS patients has lead to this milestone. A phase III trial is the next step.
Collaborate with AKIGAI
AKIGAI is looking for partners and collaborators to help realize EGFR-inhibitors for use against neuropathic pain.
We are proud to be
working with
